1 / 31

Global mRNA Vaccines and Therapeutics Market Research Report - FY26

The Global mRNA Vaccines and Therapeutics Market is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26.

Sonu22
Download Presentation

Global mRNA Vaccines and Therapeutics Market Research Report - FY26

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. marknteladvisors.com Global mRNA Vaccines and Therapeutics Market Analysis, 2021

  2. Document Outline Table of Content Market Segmentation, Scope of Work 02 Research Process & Methodology Key questions answered in the report, Research process, Primary Research, Secondary Research, Respondent Profile 17 Sample Pages Global mRNA Vaccines and Therapeutics Market Analysis, 2021 24 66 Commercials Company Profile About the company 68 70 Contact Details 2 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  3. Market Segmentation Global mRNA Vaccines and Therapeutics Market By mRNA Type By Application By Region • Nucleoside-Modified mRNA (modRNA) • Unmodified mRNA • Self-Amplifying mRNA • COVID mRNA Application • Commercialised Vaccine • mRNA-1273 • BNT162b2 • Pipeline Vaccines • CVnCoV • LUNAR-COV19 • MRT5500 • DS-5670 • Non-COVID mRNA Application • Immuno-Oncology • Cardiology • Endocrinology • Haematology • Other infectious & rare diseases • North America • The US • Canada • Mexico • South America • Brazil • Mexico • Argentina • Others • Europe • Germany • The UK • France • Italy • Spain • Others • Middle East & Africa • UAE • South Africa • Saudi Arabia • Others • Asia-Pacific • India • China • Japan • South Korea • Australia • Others By End Users • Hospitals & healthcare Clinics • Research Organisation& Institutions • Others By Company • Arcturus Therapeutics Holdings Inc. • BioNTech • CureVac N.V. • ethris GmbH • Gennova Biopharmaceuticals Ltd • GlaxoSmithKline plc • Moderna • Pantherna Therapeutics GmbH • Pfizer • Providence Therapeutics • Providence Therapeutics • Silence Therapeutics • Translate Bio • VersamebAG • Verve Therapeutics, Inc. 3 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  4. Base Year: 2020 Table of Content (1/13) Forecast Year: (2021-26) Table of Content 1. Introduction 1.1. Product Definition 1.2. Research Process 1.3. Assumptions 1.4. Market Segmentation 2. Executive Summary 3. Impact of COVID-19 on Global mRNA Vaccines and Therapeutics Market 4. Global mRNA Vaccines and Therapeutics Market Analysis Trends & Insights 5. Global mRNA Vaccines and Therapeutics Market Intellectual Property Rights Analysis 6. Global mRNA Vaccines and Therapeutics Market Analysis Hotspots & Opportunities 7. Global mRNA Vaccines and Therapeutics Market Analysis Government Regulations 8. Global mRNA Vaccines and Therapeutics Market Use Case Scenario Comparison (COVID-19 vs Non COVID-19) 9. Global mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 9.1. Market Size & Analysis 9.1.1.By Revenues 9.2. Market Share & Analysis 9.2.1.By mRNA Type 9.2.1.1. Nucleoside-Modified mRNA (modRNA) 9.2.1.2. Unmodified mRNA 9.2.1.3. Self-Amplifying mRNA 4 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  5. Base Year: 2020 Table of Content (2/13) Forecast Year: (2021-26) Table of Content 9.2.2.By Application Type 9.2.2.1. COVID mRNA Application 9.2.2.1.1. Commercialised Vaccine 9.2.2.1.1.1. mRNA-1273 9.2.2.1.1.2. BNT162b2 9.2.2.1.2. Pipeline Vaccines 9.2.2.1.2.1. CVnCoV 9.2.2.1.2.2. LUNAR-COV19 9.2.2.1.2.3. MRT5500 9.2.2.1.2.4. DS-5670 9.2.2.2. Non-COVID mRNA Application 9.2.2.2.1. Immuno-Oncology 9.2.2.2.2. Cardiology 9.2.2.2.3. Endocrinology 9.2.2.2.4. Haematology 9.2.2.2.5. Other infectious & rare diseases 9.2.3.By End Users 9.2.3.1. Hospitals & healthcare Clinics 9.2.3.2. Research Organisation & Institutions 9.2.3.3. Others 5 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  6. Base Year: 2020 Table of Content (3/13) Forecast Year: (2021-26) Table of Content 9.2.4.By Region 9.2.4.1. North America 9.2.4.2. South America 9.2.4.3. Europe 9.2.4.4. Asia-Pacific 9.2.4.5. Middle East & Africa 9.2.5.By Competitor 9.2.5.1. Competition Characteristics 9.2.5.2. Competitor Alignment in Competition Matrix 10. North America mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 10.1. Market Size & Analysis 10.1.1. By Revenues 10.2. Market Share & Analysis 10.2.1. By mRNA Type 10.2.2. By Application Type 10.2.3. By End User 10.2.4. By Country 10.2.4.1. The US mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 10.2.4.1.1. Market Size & Analysis 10.2.4.1.1.1. By Revenues 6 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  7. Base Year: 2020 Table of Content (4/13) Forecast Year: (2021-26) Table of Content 10.2.4.1.2. Market Share & Analysis 10.2.4.1.2.1. By mRNA Type 10.2.4.1.2.2. By Application Type 10.2.4.1.2.3. By End User 10.2.4.2. Canada mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 10.2.4.2.1. Market Size & Analysis 10.2.4.2.1.1. By Revenues 10.2.4.2.2. Market Share & Analysis 10.2.4.2.2.1. By mRNA Type 10.2.4.2.2.2. By Application Type 10.2.4.2.2.3. By End User 10.2.4.3. Mexico mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 10.2.4.3.1. Market Size & Analysis 10.2.4.3.1.1. By Revenues 10.2.4.3.2. Market Share & Analysis 10.2.4.3.2.1. By mRNA Type 10.2.4.3.2.2. By Application Type 10.2.4.3.2.3. By End User 11. South America mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 11.1. Market Size & Analysis 7 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  8. Base Year: 2020 Table of Content (5/13) Forecast Year: (2021-26) Table of Content 11.1.1. By Revenues 11.2. Market Share & Analysis 11.2.1. By mRNA Type 11.2.2. By Application Type 11.2.3. By End User 11.2.4. By Country 11.2.4.1. Brazil mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 11.2.4.1.1. Market Size & Analysis 11.2.4.1.1.1. By Revenues 11.2.4.1.2. Market Share & Analysis 11.2.4.1.2.1. By mRNA Type 11.2.4.1.2.2. By Application Type 11.2.4.1.2.3. By End User 11.2.4.2. Argentina mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 11.2.4.2.1. Market Size & Analysis 11.2.4.2.1.1. By Revenues 11.2.4.2.2. Market Share & Analysis 11.2.4.2.2.1. By mRNA Type 11.2.4.2.2.2. By Application Type 11.2.4.2.2.3. By End User 8 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  9. Base Year: 2020 Table of Content (6/13) Forecast Year: (2021-26) Table of Content 12. Europe mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.1. Market Size & Analysis 12.1.1. By Revenues 12.2. Market Share & Analysis 12.2.1. By mRNA Type 12.2.2. By Application Type 12.2.3. By End User 12.2.4. By Country 12.2.4.1. The UK mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.2.4.1.1. Market Size & Analysis 12.2.4.1.1.1. By Revenues 12.2.4.1.2. Market Share & Analysis 12.2.4.1.2.1. By mRNA Type 12.2.4.1.2.2. By Application Type 12.2.4.1.2.3. By End User 12.2.4.2. Germany mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.2.4.2.1. Market Size & Analysis 12.2.4.2.1.1. By Revenues 12.2.4.2.2. Market Share & Analysis 12.2.4.2.2.1. By mRNA Type 9 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  10. Base Year: 2020 Table of Content (7/13) Forecast Year: (2021-26) Table of Content 12.2.4.2.2.2. By Application Type 12.2.4.2.2.3. By End User 12.2.4.3. France mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.2.4.3.1. Market Size & Analysis 12.2.4.3.1.1. By Revenues 12.2.4.3.2. Market Share & Analysis 12.2.4.3.2.1. By mRNA Type 12.2.4.3.2.2. By Application Type 12.2.4.3.2.3. By End User 12.2.4.4. Italy mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.2.4.4.1. Market Size & Analysis 12.2.4.4.1.1. By Revenues 12.2.4.4.2. Market Share & Analysis 12.2.4.4.2.1. By mRNA Type 12.2.4.4.2.2. By Application Type 12.2.4.4.2.3. By End User 12.2.4.5. Spain mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12.2.4.5.1. Market Size & Analysis 12.2.4.5.1.1. By Revenues 12.2.4.5.2. Market Share & Analysis 10 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  11. Base Year: 2020 Table of Content (8/13) Forecast Year: (2021-26) Table of Content 12.2.4.5.2.1. By mRNA Type 12.2.4.5.2.2. By Application Type 12.2.4.5.2.3. By End User 13. Asia-Pacific mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 13.1. Market Size & Analysis 13.1.1. By Revenues 13.2. Market Share & Analysis 13.2.1. By mRNA Type 13.2.2. By Application Type 13.2.3. By End User 13.2.4. By Country 13.2.4.1. China mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 13.2.4.1.1. Market Size & Analysis 13.2.4.1.1.1. By Revenues 13.2.4.1.2. Market Share & Analysis 13.2.4.1.2.1. By mRNA Type 13.2.4.1.2.2. By Application Type 13.2.4.1.2.3. By End User 13.2.4.2. India mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 13.2.4.2.1. Market Size & Analysis 11 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  12. Base Year: 2020 Table of Content (9/13) Forecast Year: (2021-26) Table of Content 13.2.4.2.1.1. By Revenues 13.2.4.2.2. Market Share & Analysis 13.2.4.2.2.1. By mRNA Type 13.2.4.2.2.2. By Application Type 13.2.4.2.2.3. By End User 13.2.4.3. Japan mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 13.2.4.3.1. Market Size & Analysis 13.2.4.3.1.1. By Revenues 13.2.4.3.2. Market Share & Analysis 13.2.4.3.2.1. By mRNA Type 13.2.4.3.2.2. By Application Type 13.2.4.3.2.3. By End User 13.2.4.4. South Korea mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 13.2.4.4.1. Market Size & Analysis 13.2.4.4.1.1. By Revenues 13.2.4.4.2. Market Share & Analysis 13.2.4.4.2.1. By mRNA Type 13.2.4.4.2.2. By Application Type 13.2.4.4.2.3. By End User 13.2.4.5. Australia mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 12 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  13. Base Year: 2020 Table of Content (10/13) Forecast Year: (2021-26) Table of Content 13.2.4.5.1. Market Size & Analysis 13.2.4.5.1.1. By Revenues 13.2.4.5.2. Market Share & Analysis 13.2.4.5.2.1. By mRNA Type 13.2.4.5.2.2. By Application Type 13.2.4.5.2.3. By End User 14. Middle East & Africa mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 14.1. Market Size & Analysis 14.1.1. By Revenues 14.2. Market Share & Analysis 14.2.1. By mRNA Type 14.2.2. By Application Type 14.2.3. By End User 14.2.4. By Country 14.2.4.1. UAE mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 14.2.4.1.1. Market Size & Analysis 14.2.4.1.1.1. By Revenues 14.2.4.1.2. Market Share & Analysis 14.2.4.1.2.1. By mRNA Type 14.2.4.1.2.2. By Application Type 13 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  14. Base Year: 2020 Table of Content (11/13) Forecast Year: (2021-26) Table of Content 14.2.4.1.2.3. By End User 14.2.4.2. Saudi Arabia mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 14.2.4.2.1. Market Size & Analysis 14.2.4.2.1.1. By Revenues 14.2.4.2.2. Market Share & Analysis 14.2.4.2.2.1. By mRNA Type 14.2.4.2.2.2. By Application Type 14.2.4.2.2.3. By End User 14.2.4.3. South Africa mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F 14.2.4.3.1. Market Size & Analysis 14.2.4.3.1.1. By Revenues 14.2.4.3.2. Market Share & Analysis 14.2.4.3.2.1. By mRNA Type 14.2.4.3.2.2. By Application Type 14.2.4.3.2.3. By End User 15. Global mRNA Vaccines and Therapeutics Market Analysis Dynamics 15.1. Growth Drivers 15.2. Challenges 15.3. Impact Analysis 16. Global mRNA Vaccines and Therapeutics Market Key Strategic Imperatives for Success & Growth 14 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  15. Base Year: 2020 Table of Content (12/13) Forecast Year: (2021-26) Table of Content 17. Competitive Benchmarking 17.1.Competition Matrix 17.1.1. Product Portfolio 17.1.2. Target Markets 17.1.3. Target Security Type 17.1.4. Research & Development 17.1.5. Strategic Alliances 17.1.6. Strategic Initiatives 17.2.Company Profiles (Business Description, Product Offering, Target Markets, Assets, Strategic Alliances or Partnerships, etc.) 17.2.1. Arcturus Therapeutics Holdings Inc. 17.2.2. BioNTech 17.2.3. CureVac N.V. 17.2.4. ethris GmbH 17.2.5. Gennova Biopharmaceuticals Ltd 17.2.6. GlaxoSmithKline plc 17.2.7. Moderna 17.2.8. Pantherna Therapeutics GmbH 17.2.9. Pfizer 17.2.10. Providence Therapeutics 17.2.11. Providence Therapeutics 15 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  16. Base Year: 2020 Table of Content (13/13) Forecast Year: (2021-26) Table of Content 17.2.12. Silence Therapeutics 17.2.13. Translate Bio 17.2.14. Versameb AG 17.2.15. Verve Therapeutics, Inc. 18. Disclaimer 16 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  17. Document Outline Table of Content Market Segmentation, Scope of Work 02 Research Process & Methodology Key questions answered in the report, Research process, Primary Research, Secondary Research, Respondent Profile 17 Sample Pages Global mRNA Vaccines and Therapeutics Market Analysis, 2021 24 66 Commercials Company Profile About the company 68 70 Contact Details 17 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  18. Global mRNA Vaccines and Therapeutics Market Outlook, 2020- 2026F Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  19. Global mRNA Vaccines and Therapeutics Market Analysis, 2020-2026F (1/5) Figure XX: Global mRNA Vaccines and Therapeutics Market Revenues (USD Million), 2020-2026F Revenue: XX% CAGR 2020 2021F 2022F 2023F 2024F 2025F 2026F Source: MarkNtel Advisors, E: Estimated, F: Forecast • The global mRNA vaccines and therapeutics market is expected to witness massive growth, particularly during 2020 - 2022, majorly attributing to the current increase in the burden of COVID-19 cases, rising uptake of research projects focusing on mRNA vaccine development, increasing fund infusions from private and government organizations, favorable regulatory scenario, and growing focus on establishing business synergies, among others. The continued significant investments by the pharmaceutical companies to meet the current demand and the growing adoption of mRNA-based vaccines by the government of the developed and developing economies are the major factors which are expected to propel the growth of the global mRNA vaccines and therapeutics market (by COVID-19 vaccines), particularly during 2020 – 2022. 19 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  20. Global mRNA Vaccines and Therapeutics Market, By mRNA Type (1/5) Figure XX: Global mRNA Vaccines and Therapeutics Market Share (%) 2020 & 2026, & Market Revenue (USD Million), By mRNA Type, 2020-2026F Market Share, By mRNA Type Market Size, By mRNA Type (USD Million) Inner Circle: 2020; Outer Circle: 2026 2020 2021 2022 2023 2024 2025 2026 Nucleoside-Modified mRNA (modRNA) XX XX XX XX XX XX XX XX XX XX XX XX XX XX Unmodified mRNA XX XX XX XX XX XX XX Self-Amplifying mRNA Nucleoside-Modified mRNA (modRNA) Unmodified mRNA Self-Amplifying mRNA *These are dummy charts and do not represent actual value Source: MarkNtel Advisors • The mRNA-based vaccines and therapeutics have become a prominent technology in recent years for the prevention and treatment of infectious diseases, including COVID-19, cancer, and rare diseases, among others. The mRNA type and its delivery strategies effectively facilitate effective presentation and expression of antigens and immune stimulation. The use of appropriate mRNA type and its formulation and delivery methods significantly boosts vaccine and therapeutic efficacy, which is also influenced by the route of administration in patients. The type of mRNA which is being currently used for vaccines and therapeutics typically includes nucleoside- modified mRNA, unmodified mRNA, and self-amplifying mRNA. As of Q4 2020, the global mRNA vaccines and therapeutics market for COVID-19 (by mRNA type) was dominated by nucleoside-modified mRNA, with a 100% share of the market, which is anticipated to reach 20 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  21. Global mRNA Vaccines and Therapeutics Market, By Application (2/8) Commercialised Vaccines • With the emergence of public health emergencies due to the COVID-19 pandemic, extensive research has been conducted to discover new technologies for vaccines that are safe, easy to produce, and highly efficacious. Scientists along with the pharmaceutical companies have recently discovered mRNA-based vaccines, which are now being considered as one of the most efficacious vaccines for preventing COVID- 19. The mRNA-based COVID-19 vaccines are highly potent to facilitate cells to generate a piece of SARS-CoV-2 specific proteins which can trigger an immune response in the body, thereby offering prevention against the virus. The mRNA-based COVID-19 vaccines developed by Moderna, Inc. and BioNTech SE/Pfizer Inc. have shown impressive results in the late-stage clinical trials pertaining to its safety and efficacy to prevent COVID-19. As of March 31, 2021, mRNA-based COVID-19 vaccines such as mRNA-1273, developed by Moderna, Inc., and BNT162B2, jointly developed by BioNTech SE and Pfizer Inc., have been given emergency use authorizations and conditional marketing authorizations by the regulatory authorities in different parts of the world, further giving them the permission to commercialize their respective products to support vaccination strategies. Figure XX: Global Revenue for COVID-19 mRNA Vaccines (Commercialized), $Million, Q4 2020-Q4 2025 mRNA-1273 BNT162b2 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Source: MarkNtel Advisors 21 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  22. Global mRNA Vaccines and Therapeutics Market Revenue Share, By Company (6/19) Figure XX: Global mRNA Vaccines and Therapeutics Market Revenue Share (%), By Company, 2020 & 2026F Others (USD XX Million) BioNtech SE/ Pfizer (USD XXX Million)  XX  XX XX XX  XX  XX  XX  XX XX XX (USD XX Million) Moderna Inc (USD XXX Million) XX USD XX Billion  XX  XX  XX  XX  XX  XX XX XX XX (USD XXX Million) Cure Vac AG (USD XXX Million)  XXX  XX  XXX  XX  XXX  XX Source: MarkNtel Advisors Primary Surveys, Annual Reports, Press Releases 22 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  23. North America mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  24. North America mRNA Vaccines and Therapeutics Market Outlook, 2020-2026F Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  25. North America mRNA Vaccines and Therapeutics Market Analysis, 2020-2026F (1/5) Figure XX: North America mRNA Vaccines and Therapeutics Market Revenues (USD Million), 2020-2026F Revenue: XX% CAGR 2020 2021F 2022F 2023F 2024F 2025F 2026F Source: MarkNtel Advisors, E: Estimated, F: Forecast • The North America region majorly comprises the U.S. and Canada. The U.S. dominated the global mRNA vaccines and therapeutics market (by COVID-19 vaccines) on account of various prominent factors. Current market growth (Q4 2020 – Q4 2022) is attributed to significantly growing fund infusions for mRNA vaccine development, high rise in the pipeline products, presence of established and emerging pharmaceutical companies, presence of ultracold manufacturing and supply chains, and increasing awareness about mRNA- based COVID-19 vaccines, among others. In North America, several established mRNA vaccine manufacturers and developers are focusing on bringing advanced products to the market for supporting the country’s immunization strategies. Large and small market players are investing heavily in research and development and increasing their manufacturing capacities by incorporating business synergies and funding activities in order to capture market share. 25 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  26. North America mRNA Vaccines and Therapeutics Market, By mRNA Type (1/5) Figure XX: North America mRNA Vaccines and Therapeutics Market Share (%) 2020 & 2026, & Market Revenue (USD Million), By mRNA Type, 2020-2026F Market Share, By mRNA Type Market Size, By mRNA Type (USD Million) Inner Circle: 2020; Outer Circle: 2026 2020 2021 2022 2023 2024 2025 2026 Nucleoside-Modified mRNA (modRNA) XX XX XX XX XX XX XX XX XX XX XX XX XX XX Unmodified mRNA XX XX XX XX XX XX XX Self-Amplifying mRNA Nucleoside-Modified mRNA (modRNA) Unmodified mRNA Self-Amplifying mRNA *These are dummy charts and do not represent actual value Source: MarkNtel Advisors • XX • XX • XX • XX 26 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  27. North America mRNA Vaccines and Therapeutics Market, By Application (1/14) Figure XX: North America mRNA Vaccines and Therapeutics Market Revenue (USD Million), By Application, 2020-2026F 2020 2021 2022 2023 2024 2025 2026 XX XX XX XX XX XX XX COVID mRNA Application XX XX XX XX XX XX XX Commercialised Vaccine XX XX XX XX XX XX XX mRNA-1273 XX XX XX XX XX XX XX BNT162b2 XX XX XX XX XX XX XX Pipeline Vaccines XX XX XX XX XX XX XX CVnCoV XX XX XX XX XX XX XX LUNAR-COV19 XX XX XX XX XX XX XX MRT5500 XX XX XX XX XX XX XX DS-5670 XX XX XX XX XX XX XX Non-COVID mRNA Application XX XX XX XX XX XX XX Immuno-Oncology XX XX XX XX XX XX XX Cardiology XX XX XX XX XX XX XX Endocrinology XX XX XX XX XX XX XX Haematology XX XX XX XX XX XX XX Other infectious & rare diseases Source: MarkNtel Advisors 27 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  28. The US mRNA Vaccines and Therapeutics Market Outlook, 2020- 2026F Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  29. The US mRNA Vaccines and Therapeutics Market Analysis, 2020-2026F (1/5) Figure XX: The US mRNA Vaccines and Therapeutics Market Revenues (USD Million), 2020-2026F Revenue: XX% CAGR 2020 2021F 2022F 2023F 2024F 2025F 2026F Source: MarkNtel Advisors, E: Estimated, F: Forecast • With multiple mRNA-based vaccines currently advancing toward clinical development, the research and development for mRNA-based vaccines in the U.S. continue to grow at a fast pace. This is majorly attributed to the high fund infusions from the private and government organizations to expedite the development of the mRNA-based vaccine in order to establish a robust vaccination strategy. For instance, in April 2020, Moderna, Inc. received a fund infusion of $483 million from the Biomedical Advanced Research and Development Authority (BARDA) for expediting the development of the company’s mRNA-based COVID-19 vaccine candidate, mRNA-1273, against SARA-CoV-2. Additionally, with the favorable regulatory scenario in the country, the companies are also focusing on expedited commercialization of their respective mRNA-based COVID-19 vaccines. For instance, in March 2020, Moderna, Inc. successfully received Fast Track Designation (FDA) from the FDA for the company's potential mRNA-based COVID-19 vaccine, mRNA-1723, against SARS-CoV-2 infection. 29 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  30. Document Outline Table of Content Market Segmentation, Scope of Work 02 Research Process & Methodology Key questions answered in the report, Research process, Primary Research, Secondary Research, Respondent Profile 17 Sample Pages Global mRNA Vaccines and Therapeutics Market Analysis, 2021 24 Commercials 66 Company Profile About the Company 68 70 Contact Details 30 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

  31. +1 604 800 2671, +91 8719999009 sales@marknteladvisors.com 31 Copyright 2021. Reproduction is forbidden unless authorized. All rights reserved.

More Related